News

Fosaprepitant dimeglumine (Emend for injection) received FDA approval as a single-dose in combination with other antiemetic agents for the prevention of delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Short-course radiation therapy and three cycles of chemotherapy administered before surgery reduced side effects and improved overall survival (OS) when compared with standard chemoradiation for patients with locally advanced rectal cancer, new research has found.

This survey is open to any woman diagnosed with ovarian, fallopian tube, or primary peritoneal cancer, regardless of whether or not you have had genetic counseling or testing.